PL1673107T3 - Kompozycja farmaceutyczna zawierająca selektywnego agonistę receptora imidazoliny I1 i bloker receptora angiotensyny II - Google Patents

Kompozycja farmaceutyczna zawierająca selektywnego agonistę receptora imidazoliny I1 i bloker receptora angiotensyny II

Info

Publication number
PL1673107T3
PL1673107T3 PL04766880T PL04766880T PL1673107T3 PL 1673107 T3 PL1673107 T3 PL 1673107T3 PL 04766880 T PL04766880 T PL 04766880T PL 04766880 T PL04766880 T PL 04766880T PL 1673107 T3 PL1673107 T3 PL 1673107T3
Authority
PL
Poland
Prior art keywords
angiotensin
selective
pharmaceutical composition
receptor
imidazoline
Prior art date
Application number
PL04766880T
Other languages
English (en)
Inventor
Dominique Baum
Gerhard-Wilhelm Bielenberg
Bernd Boedecker
Dirk Thormaehlen
Original Assignee
Abbott Laboratories Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories Gmbh filed Critical Abbott Laboratories Gmbh
Publication of PL1673107T3 publication Critical patent/PL1673107T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL04766880T 2003-10-10 2004-10-07 Kompozycja farmaceutyczna zawierająca selektywnego agonistę receptora imidazoliny I1 i bloker receptora angiotensyny II PL1673107T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03103763 2003-10-10
EP04766880A EP1673107B1 (en) 2003-10-10 2004-10-07 Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker
PCT/EP2004/052468 WO2005039639A2 (en) 2003-10-10 2004-10-07 Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker

Publications (1)

Publication Number Publication Date
PL1673107T3 true PL1673107T3 (pl) 2008-06-30

Family

ID=34486329

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04766880T PL1673107T3 (pl) 2003-10-10 2004-10-07 Kompozycja farmaceutyczna zawierająca selektywnego agonistę receptora imidazoliny I1 i bloker receptora angiotensyny II

Country Status (19)

Country Link
US (2) US20050143435A1 (pl)
EP (1) EP1673107B1 (pl)
JP (1) JP4829115B2 (pl)
KR (1) KR101137084B1 (pl)
CN (1) CN100453117C (pl)
AT (1) ATE390148T1 (pl)
AU (1) AU2004283047B2 (pl)
BR (1) BRPI0415198A (pl)
CA (1) CA2541867C (pl)
DE (1) DE602004012763T2 (pl)
ES (1) ES2304624T3 (pl)
IL (1) IL174762A (pl)
MX (1) MXPA06004029A (pl)
NO (1) NO335735B1 (pl)
PL (1) PL1673107T3 (pl)
RU (1) RU2362561C2 (pl)
UA (1) UA83077C2 (pl)
WO (1) WO2005039639A2 (pl)
ZA (1) ZA200601804B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4675586B2 (ja) * 2004-06-23 2011-04-27 壽製薬株式会社 高血圧症及び血清高尿酸血症の重複発症の治療のための薬剤
WO2007050485A2 (en) * 2005-10-25 2007-05-03 Merck & Co., Inc. Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
WO2007144175A2 (en) 2006-06-16 2007-12-21 Lek Pharmaceuticals D.D. Pharmaceutical composition comprising hydrochlorothiazide and telmisartan
EP2018885B1 (en) 2007-07-25 2011-02-09 Schott forma vitrum ag Application device
EP2203158A4 (en) * 2007-10-30 2012-12-26 Reddys Lab Ltd Dr PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE
MX2011014005A (es) * 2009-06-30 2012-04-30 Sanofi Sa Composiciones de sodis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su uso terapeutica.
CN102850331B (zh) * 2012-09-17 2015-05-20 符爱清 一种化合物的制备方法
MD4412C1 (ro) * 2014-08-29 2016-11-30 Алёна ДУРНЯ Utilizare a acidului 4-({2-butil-5-[2-carboxi-2-(tiofen-2-ilmetil)et-1-en-1-il] -1H-imidazol-1-il}metil) benzoic pentru ameliorarea elasticităţii vasculare în profilaxia complicaţiilor de geneză hipertensivă
PL424452A1 (pl) * 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
RU2734281C1 (ru) * 2019-06-11 2020-10-14 Федеральное государственное бюджетное учреждение науки Институт теоретической и экспериментальной биофизики Российской академии наук (ИТЭБ РАН) Композиция для лечения артериальной гипертензии и ассоциированных с ней патологий сердечно-сосудистой системы
EP3986412A4 (en) * 2019-06-21 2023-11-15 The Broad Institute, Inc. Agents for reversing toxic proteinopathies
GB202006074D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
WO2025002914A1 (en) 2023-06-26 2025-01-02 Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) Antagonists of the imidazoline-1 receptor for use in the prevention and/or treatment of an autoinflammatory or autoimmune disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5354867A (en) * 1988-12-06 1994-10-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
ATE134624T1 (de) * 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
JP2707390B2 (ja) * 1992-05-22 1998-01-28 壽製薬株式会社 シクロヘプトイミダゾ−ル誘導体及びその製造方法並びにこれを含有する薬剤
DE4423177A1 (de) * 1994-07-01 1996-01-04 Kali Chemie Pharma Gmbh Antihyperglykämisch wirksame Arzneimittel
US5972948A (en) * 1994-07-01 1999-10-26 Solvay Pharmaceuticals Gmbh Method of inhibiting hyperglycemia and pharmaceutical composition for use therein
ZA981029B (en) * 1997-02-11 1999-08-10 Lilly Co Eli Pharmaceutical agents.
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
JP4107831B2 (ja) * 2000-11-21 2008-06-25 第一三共株式会社 医薬組成物
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
HU0200980D0 (pl) * 2002-03-14 2002-05-29 Gabor S Pal Dr
AU2003268493A1 (en) * 2002-09-11 2004-04-30 Merck & Co., Inc. Piperazine urea derivatives as melanocortin-4 receptor agonists

Also Published As

Publication number Publication date
CN100453117C (zh) 2009-01-21
KR20060117912A (ko) 2006-11-17
IL174762A0 (en) 2006-08-20
RU2006115796A (ru) 2007-11-27
KR101137084B1 (ko) 2012-04-24
ATE390148T1 (de) 2008-04-15
CA2541867C (en) 2012-06-12
RU2362561C2 (ru) 2009-07-27
WO2005039639A2 (en) 2005-05-06
AU2004283047B2 (en) 2009-09-17
BRPI0415198A (pt) 2006-12-05
JP4829115B2 (ja) 2011-12-07
US20110229571A1 (en) 2011-09-22
NO335735B1 (no) 2015-02-02
DE602004012763T2 (de) 2009-05-07
US20050143435A1 (en) 2005-06-30
CN1859924A (zh) 2006-11-08
ES2304624T3 (es) 2008-10-16
WO2005039639A3 (en) 2005-08-11
CA2541867A1 (en) 2005-05-06
NO20062088L (no) 2006-07-07
EP1673107A2 (en) 2006-06-28
EP1673107B1 (en) 2008-03-26
AU2004283047A1 (en) 2005-05-06
MXPA06004029A (es) 2006-06-28
WO2005039639B1 (en) 2005-09-22
JP2007508276A (ja) 2007-04-05
IL174762A (en) 2010-11-30
HK1096293A1 (zh) 2007-06-01
ZA200601804B (en) 2007-05-30
UA83077C2 (ru) 2008-06-10
DE602004012763D1 (de) 2008-05-08

Similar Documents

Publication Publication Date Title
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
IL174762A0 (en) Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
ATE468853T1 (de) Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung
TW200730202A (en) Solid dosage form
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
WO2004100875A3 (en) Benzimidazoles, compositions containing such compounds and methods of use
ATE469895T1 (de) Cgrp-rezeptorantagonisten
EP1993560A4 (en) CANNABINOID RECEPTOR ANTAGONISTS / INVERSE AGONISTS TO TREAT OVERWEIGHT
GR1005052B (el) Συνθεσεις περιεχουσες αγωνιστη υποδοχεων s1p
MXPA06011924A (es) Dispositivo de liberacion continua base polimeros.
DK2049475T3 (da) Cyclohexyl-substituerede pyrrolidinoner som inhibitorer af 11-beta-hydroxysteroid dehydrogenase1
WO2008087491A3 (en) Method for treating or preventing symptoms of hormonal variations
MX2007009389A (es) Agonistas de pyy y sus usos.
ZA200409333B (en) 4-substituted imidazole-2-thiones and imidazol-2-ones as agonists of the alpha-2B and alpha-2C adrenergic receptors.
IL186089A0 (en) 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidines used as cgrp antagonists
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
GB2454620A (en) Solid dosage form of olmesartan medoxomil and amlodipine
TW200745031A (en) Acyl indoles, compositions containing such compounds and methods of use
WO2007095113A3 (en) Cpg15 and cpg15-2 compounds and inhibitors as insulin receptor and insulin-like growth factor receptor agonists and antagonists
EP1549655A4 (en) SUBSTITUTED BICYCLIC THIOPHENE DERIVATIVES, COMPOSITIONS AND METHOD OF ADMINISTRATION CONTAINING SUCH COMPOUNDS
WO2002100350A3 (en) Dopamine receptor ligands and therapeutic methods based thereon
MX2009003441A (es) Agonistas del receptor de eritropoyetina humana, composiciones, metodos y usos para prevenir o tratar condiciones relacionadas con la intolerancia a la glucosa.